We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLRN
151
DELISTED
ACELYRIN
SLRN
$264K 0.04%
53,500
+2,979
+6% +$15.4K
UCFI
152
CN Healthy Food Tech Group
UCFI
$255K 0.04%
+25,000
New +$253K
VYGR icon
153
Voyager Therapeutics
VYGR
$189M
$238K 0.04%
40,634
+22,000
+118% +$160K
JBIO
154
Jade Biosciences
JBIO
$1.35B
$236K 0.04%
3,231
-3,824
-54% -$247K
ARWR icon
155
Arrowhead Research
ARWR
$12.1B
$227K 0.04%
11,705
+5,805
+98% +$142K
CMRX
156
DELISTED
Chimerix, Inc.
CMRX
$224K 0.04%
240,557
+62,328
+35% +$55.6K
ONC
157
BeOne Medicines Ltd
ONC
$36.7B
$220K 0.04%
978
-10,122
-91% -$1.82M
TENX icon
158
Tenax Therapeutics
TENX
$498M
$216K 0.04%
+62,423
New +$226K
VTYX
159
DELISTED
Ventyx Biosciences
VTYX
$214K 0.03%
97,955
+85,000
+656% +$195K
BSX icon
160
Boston Scientific
BSX
$71.4B
$210K 0.03%
+2,500
New +$197K
VRDN icon
161
Viridian Therapeutics
VRDN
$2.55B
$209K 0.03%
9,206
+1,206
+15% +$19.7K
TERN
162
DELISTED
Terns Pharmaceuticals
TERN
$206K 0.03%
24,702
+9,702
+65% +$79.8K
FULC icon
163
Fulcrum Therapeutics
FULC
$288M
$199K 0.03%
55,802
-312,567
-85% -$2.32M
SPRB
164
Spruce Biosciences
SPRB
$128M
$192K 0.03%
5,383
+647
+14% +$23.7K
RGNX icon
165
CALL
Regenxbio
RGNX
$745M
$187K 0.03%
+17,800
New +$217K
CTNM
166
Contineum Therapeutics
CTNM
$577M
$172K 0.03%
+8,967
New +$172K
CLDX icon
167
Celldex Therapeutics
CLDX
$3.26B
$170K 0.03%
5,000
+4,697
+1,550% +$179K
NVEI
168
DELISTED
Nuvei Corporation Subordinate Voting Shares
NVEI
$167K 0.03%
5,000
– –
TARS icon
169
CALL
Tarsus Pharmaceuticals
TARS
$2.87B
$164K 0.03%
+5,000
New +$141K
NXTC icon
170
NextCure
NXTC
$22.7M
$164K 0.03%
10,001
+2,583
+35% +$47.5K
KALV
171
DELISTED
KalVista Pharmaceuticals
KALV
$164K 0.03%
14,143
+2,123
+18% +$26.7K
BOLT icon
172
Bolt Biotherapeutics
BOLT
$7.44M
$159K 0.03%
12,248
+2,948
+32% +$40.6K
ABEO icon
173
Abeona Therapeutics
ABEO
$393M
$154K 0.03%
24,322
-88,803
-78% -$464K
BKHA
174
Black Hawk Acquisition Corp
BKHA
$154K 0.03%
+15,000
New +$153K
GALT icon
175
PUT
Galectin Therapeutics
GALT
$212M
$152K 0.02%
+55,300
New +$136K
5 6
7
8 9

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.